Table 3.
Item | Exp. 1 | Exp. 2 | |||||||
---|---|---|---|---|---|---|---|---|---|
Treatment group1 | SEM | P-value | Treatment group2 | SEM | P-value | ||||
CON-1 | APK | CON-2 | K88 | K88+APK | |||||
OM, % | 77.11 | 76.48 | 0.56 | 0.637 | 75.66 | 69.31 | 74.23 | 1.37 | 0.129 |
CP, % | 70.33 | 71.33 | 0.68 | 0.539 | 69.66a | 54.06b | 63.50c | 2.39 | <0.01 |
Crude fat, % | 69.23 | 70.54 | 1.27 | 0.662 | 71.03a | 51.62b | 67.01a | 3.50 | 0.024 |
Ca, % | 53.10 | 50.13 | 1.75 | 0.459 | 56.92 | 40.24 | 43.58 | 0.04 | 0.141 |
P, % | 47.10 | 46.61 | 1.31 | 0.874 | 45.33 | 32.33 | 37.67 | 3.04 | 0.228 |
a–cMeans within a row with different superscripts differ (P < 0.05).
1CON-1 = piglets with an intraperitoneal (i.p.) injection of an equivalent volume (1 mL) of PBS; APK = piglets with an i.p. injection of antimicrobial peptide KR-32. n = 6 for the CON-1 group and n = 6 for the APK group.
2CON-2 = piglets with an oral administration of fresh Luria–Bertani broth (50 mL) followed by an i.p. injection of an equivalent volume of PBS; K88 = piglets orally challenged with 1 × 1010 cfu ETEC K88 on day 1 followed by an i.p. injection of an equivalent volume (1 mL) of PBS; K88 + APK = piglets orally challenged with 1 × 1010 cfu ETEC K88 on day 1 followed by an i.p. injection of 0.6 mg/kg KR-32. n = 6 for the CON-2 group, n = 5 for the K88 group, and n = 5 for the K88 + APK group.